Literature DB >> 2844397

Influence of WR2721 on DNA cross-linking by nitrogen mustard in normal mouse bone marrow and leukemia cells in vivo.

W J DeNeve1, C K Everett, J E Suminski, F A Valeriote.   

Abstract

In previous studies we showed that WR2721 enhanced nitrogen mustard (HN2) cytotoxicity to AKR mouse leukemia. Simultaneously, it protected normal bone marrow from drug cytotoxicity. In this study, the method of alkaline elution was used to measure the modifications of HN2 induced DNA damage in the same animal model. In leukemia cells, no significant differences in DNA-DNA interstrand cross-links were observed between mice treated with WR2721 and HN2 and mice treated with HN2 alone. In normal bone marrow, DNA-DNA cross-linking was decreased by about 50% in mice treated by WR2721 and HN2. The difference was significant (P = 0.01). In leukemia, half-time of repair was 73 min for HN2 and 83 for WR2721 and HN2 treated mice, while in normal bone marrow, respectively, 73 and 64 min were calculated. WR2721 modulation significantly decreases DNA-protein cross-links in leukemia cells (P less than 0.05). This decrease was observed for early as well as for late DNA-protein cross-links. In normal bone marrow cells, only early DNA-protein cross-links were decreased. The meaning of this observation is unclear.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2844397

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Discrepancy between cytotoxicity and DNA interstrand crosslinking of carboplatin and cisplatin in vivo.

Authors:  W DeNeve; F Valeriote; E Tapazoglou; C Everett; A Khatana; T Corbett
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

2.  In vitro protection from cisplatin-induced neurotoxicity by amifostine and its metabolite WR1065.

Authors:  C C Verstappen; A A Geldof; T J Postma; J J Heimans
Journal:  J Neurooncol       Date:  1999-08       Impact factor: 4.130

Review 3.  Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.

Authors:  C R Culy; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Experimental basis for increasing the therapeutic index of carboplatin in brain tumor therapy by pretreatment with WR compounds.

Authors:  F Doz; M E Berens; D R Spencer; D V Dougherty; M L Rosenblum
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

5.  Protective effect of O-phenanthroline against mechlorethamine toxicity in the rat liver slice system and in the guinea pig skin.

Authors:  U Wormser; A Nyska
Journal:  Arch Toxicol       Date:  1991       Impact factor: 5.153

Review 6.  Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.

Authors:  C M Spencer; K L Goa
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

7.  The protective effect of amifostine on ultraviolet B-exposed xeroderma pigmentosum mice.

Authors:  Sl Henry; D Christiansen; Fr Kazmier; Cl Besch-Williford; Mj Concannon
Journal:  Ecancermedicalscience       Date:  2010-09-22

8.  p53 protein regulates the effects of amifostine on apoptosis, cell cycle progression, and cytoprotection.

Authors:  E J Lee; M Gerhold; M W Palmer; R D Christen
Journal:  Br J Cancer       Date:  2003-03-10       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.